Skip to content
DataLookout
Menu

EDELVAISSNCT06656104

Impact of a Multi-infusion Strategy in Neonatology on the Rate of Central Line-associated Bloodstream Infections

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Nov 1, 2026 to Aug 14, 2027
    • Eligibility criteria expanded, about 11 words
    • Enrollment increased: 455 → 569 participants
    • Site details revised at 3 of 3 sites
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2025 to Jan 14, 2025
    • Site details revised at 3 of 3 sites
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of central line associated bloodstream infections (CLABSI) in very preterm infants
Timeframe: Up to six months

Arms and interventions

Reference period

The center used the routine strategy based on the usual catheters and infusion systems (reference strategy). The duration of this period depending to the randomization of the center (i.e. 4 months, 8 months or 12 months)

Experimental period

At the end of the reference period, center will progressively switch to the new multi-infusion strategy (experimental strategy). The center used the Multiline Neo system to the routine strategy. The duration of this period depending to the randomization of the center (i.e. 12 months, 8 months or 4 months)

Devices: Reference strategy, Experimental strategy

Sites

3 sites in 1 country